Vasudev Pai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Vasudev Pai has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Deepanjan Datta
Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India
4 shared publications Aravinda Pai
Department of Pharmaceutical Chemistry Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education Manipal Karnataka India
3 shared publicationsK. S. Chandrashekar
2 shared publicationsMaria Nison
Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education
2 shared publications- Maria Nison
Department of Pharmacognosy Manipal College of Pharmaceutical Sciences Manipal Academy of Higher Education Manipal India
2 shared publications Megha Kotian
Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education
2 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by Wiley in Nano Select
- Vol. 7 (9) , e70188
Molecular Mechanisms and Therapeutic Applications of Extracellular Vesicles in Remodeling of the Skin Cancer Niche
Skin cancer, encompassing melanoma and nonmelanoma types, is an escalating global health issue owing to its increasing prevalence, invasiveness, and spreading capability. Extracellular vesicles (EVs) have become pivotal agents of intercellular communication in the tumor microenvironment (TME). These nano‐ to microscale, membrane‐bound vesicles are released by tumor, stromal, and immune cells and transport bioactive substances such as proteins, lipids, and nucleic acids that influence recipient‐cell behavior. EVs are produced via endosomal sorting or plasma membrane budding, yielding exosomes and microvesicles with unique molecular signatures. In skin cancer, EV cargo mirrors, the genetic and metabolic state of the originating cell, containing abundant integrins, matrix metalloproteinases, growth factors, and regulatory microRNAs that modulate proliferation, survival, and stress responses. Tumor‐derived EVs facilitate immune evasion by delivering immune checkpoint molecules such as PD‐L1, thereby inhibiting cytotoxic T cell activity and promoting regulatory T cell expansion. They promote angiogenesis and transform fibroblasts into cancer‐associated fibroblasts, thereby aiding extracellular matrix remodeling and invasion. Moreover, EVs facilitate metastasis by creating pre‐metastatic habitats and enhancing vascular permeability. EVs are promising targets for diagnostic and therapeutic approaches at disrupt tumor‐supportive communication networks.
- 23 September 2026
- Published by Wiley in Nano Select
- Vol. 7 (9) , e70188
Open AccessMolecular Mechanisms and Therapeutic Applications of Extracellular Vesicles in Remodeling of the Skin Cancer Niche
Skin cancer, encompassing melanoma and nonmelanoma types, is an escalating global health issue owing to its increasing prevalence, invasiveness, and spreading capability. Extracellular vesicles (EVs) have become pivotal agents of intercellular communication in the tumor microenvironment (TME). These nano‐ to microscale, membrane‐bound vesicles are released by tumor, stromal, and immune cells and transport bioactive substances such as proteins, lipids, and nucleic acids that influence recipient‐cell behavior. EVs are produced via endosomal sorting or plasma membrane budding, yielding exosomes and microvesicles with unique molecular signatures. In skin cancer, EV cargo mirrors, the genetic and metabolic state of the originating cell, containing abundant integrins, matrix metalloproteinases, growth factors, and regulatory microRNAs that modulate proliferation, survival, and stress responses. Tumor‐derived EVs facilitate immune evasion by delivering immune checkpoint molecules such as PD‐L1, thereby inhibiting cytotoxic T cell activity and promoting regulatory T cell expansion. They promote angiogenesis and transform fibroblasts into cancer‐associated fibroblasts, thereby aiding extracellular matrix remodeling and invasion. Moreover, EVs facilitate metastasis by creating pre‐metastatic habitats and enhancing vascular permeability. EVs are promising targets for diagnostic and therapeutic approaches at disrupt tumor‐supportive communication networks.
- Open Access
- 21 September 2026
- Published by Springer Nature in Progress in Additive Manufacturing
- Vol. 11 (10) , 10847-10912
Structure–property engineering of additively manufactured and 3D-printed polymeric biomaterials for chronic wound management
Chronic wounds, such as diabetic ulcers, pressure sores, and surgical incisions, may develop if the natural healing process is disrupted. Traditional approaches to managing chronic wounds require the involvement of a healthcare professional, although they do not guarantee patient adherence. The use of machine tooling in the design of wound healing products has provided effective solutions to this issue. In recent years, additive manufacturing has emerged as a versatile method that has garnered the attention of researchers and healthcare professionals. Additive manufacturing involves constructing intricate structures layer-by-layer using synthetic or natural polymers. Techniques such as stereolithography and micro-extrusion bioprinting have enabled the creation of diverse products that support wound healing. Furthermore, researchers are developing personalised wound healing therapies utilising advanced 3D printing technologies. The development of bioinks containing cells and therapeutics has greatly improved wound treatment and care. This progress is especially obvious in skin replacement engineering and regeneration. Printing methods enable the integration of bioactive chemicals and cells into polymers, scaffold designs, and individualised wound dressings, leading to faster healing. Overall, this extensive review covers recent advances in additive manufacturing and bioprinted polymeric biomaterials for chronic wound healing. Graphical abstract
- 21 September 2026
- Published by Springer Nature in Progress in Additive Manufacturing
- Vol. 11 (10) , 10847-10912
Open AccessStructure–property engineering of additively manufactured and 3D-printed polymeric biomaterials for chronic wound management
Chronic wounds, such as diabetic ulcers, pressure sores, and surgical incisions, may develop if the natural healing process is disrupted. Traditional approaches to managing chronic wounds require the involvement of a healthcare professional, although they do not guarantee patient adherence. The use of machine tooling in the design of wound healing products has provided effective solutions to this issue. In recent years, additive manufacturing has emerged as a versatile method that has garnered the attention of researchers and healthcare professionals. Additive manufacturing involves constructing intricate structures layer-by-layer using synthetic or natural polymers. Techniques such as stereolithography and micro-extrusion bioprinting have enabled the creation of diverse products that support wound healing. Furthermore, researchers are developing personalised wound healing therapies utilising advanced 3D printing technologies. The development of bioinks containing cells and therapeutics has greatly improved wound treatment and care. This progress is especially obvious in skin replacement engineering and regeneration. Printing methods enable the integration of bioactive chemicals and cells into polymers, scaffold designs, and individualised wound dressings, leading to faster healing. Overall, this extensive review covers recent advances in additive manufacturing and bioprinted polymeric biomaterials for chronic wound healing. Graphical abstract
- Open Access
- 9 September 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (7) , 278
Nanosuspension-based Ocular Therapeutics for Infection Control: Integrating Mucin Interactions and Tear Film Dynamics
Ocular infections can affect the ocular surface and adnexal structures, intraocular structures, or both. Infections of the ocular surface and adnexa often
- 9 September 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (7) , 278
Open AccessNanosuspension-based Ocular Therapeutics for Infection Control: Integrating Mucin Interactions and Tear Film Dynamics
Ocular infections can affect the ocular surface and adnexal structures, intraocular structures, or both. Infections of the ocular surface and adnexa often
- 3 August 2026
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 26, 1-20
Epigenetic Modifiers and Synthetic Lethality in Cancer Therapy: Emerging Targets Beyond Traditional Approaches
As the field of anticancer drug development is constantly changing, combining synthetic lethality with epigenetic modifiers opens up new possibilities for targets that fall outside the traditional drug target range. Enzymes involved in DNA methylation and histone modification are examples of epigenetic modifiers that promote gene expression without altering the DNA sequence of the gene. These mechanisms play a key role in carcinogenesis when they are altered, as they downregulate tumor suppressor genes and overexpress oncogenic pathways. Synthetic lethality is a phenomenon in which simultaneous mutations or perturbations of two genes result in cell death, but alterations to one gene alone do not cause cell death. It was first observed in genetic research conducted on model organisms, such as fruit flies and fungi. The most well-known example of this idea from the perspective of cancer treatment is PARP inhibitors, which are effective in tumors with BRCA1/2 mutations, where further failure of DNA repair results in cell sensitization. Building on the concept of synthetic lethality, current research focuses on exploiting epigenetic flaws that are common in cancer cells. For example, when chromatin remodelers or methyltransferases cease to function, malignant cells undergo genetic rewiring, rendering them vulnerable to treatment. Recent research has produced some striking examples of synthetic-lethal drug interactions and biomarkers used in metagenomics for personalized medicine by targeting the secondary pathways used by cancer cells as a result of primary loss-of-function mutations, which selectively kill cancer cells while sparing healthy cells. The discovery of actionable epigenetic dependencies and overcoming tumor heterogeneity remain the largest challenges in translating these fascinating scientific discoveries to the clinic. The convergence of epigenetic modulators with synthetic-lethality-based therapeutic architectures is poised to define a transformative paradigm in precision oncology. By orchestrating multilayered perturbations across chromatin-regulatory networks, DNA damage–response pathways, and context-specific vulnerability nodes, this integrative strategy surpasses the limitations of conventional target-centric pharmacology and enables mechanistically rational, synergistic antitumor interventions.
- 3 August 2026
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 26, 1-20
Epigenetic Modifiers and Synthetic Lethality in Cancer Therapy: Emerging Targets Beyond Traditional Approaches
As the field of anticancer drug development is constantly changing, combining synthetic lethality with epigenetic modifiers opens up new possibilities for targets that fall outside the traditional drug target range. Enzymes involved in DNA methylation and histone modification are examples of epigenetic modifiers that promote gene expression without altering the DNA sequence of the gene. These mechanisms play a key role in carcinogenesis when they are altered, as they downregulate tumor suppressor genes and overexpress oncogenic pathways. Synthetic lethality is a phenomenon in which simultaneous mutations or perturbations of two genes result in cell death, but alterations to one gene alone do not cause cell death. It was first observed in genetic research conducted on model organisms, such as fruit flies and fungi. The most well-known example of this idea from the perspective of cancer treatment is PARP inhibitors, which are effective in tumors with BRCA1/2 mutations, where further failure of DNA repair results in cell sensitization. Building on the concept of synthetic lethality, current research focuses on exploiting epigenetic flaws that are common in cancer cells. For example, when chromatin remodelers or methyltransferases cease to function, malignant cells undergo genetic rewiring, rendering them vulnerable to treatment. Recent research has produced some striking examples of synthetic-lethal drug interactions and biomarkers used in metagenomics for personalized medicine by targeting the secondary pathways used by cancer cells as a result of primary loss-of-function mutations, which selectively kill cancer cells while sparing healthy cells. The discovery of actionable epigenetic dependencies and overcoming tumor heterogeneity remain the largest challenges in translating these fascinating scientific discoveries to the clinic. The convergence of epigenetic modulators with synthetic-lethality-based therapeutic architectures is poised to define a transformative paradigm in precision oncology. By orchestrating multilayered perturbations across chromatin-regulatory networks, DNA damage–response pathways, and context-specific vulnerability nodes, this integrative strategy surpasses the limitations of conventional target-centric pharmacology and enables mechanistically rational, synergistic antitumor interventions.
- 31 July 2026
- Published by Springer Nature
- p. 1-45
History of Vaccines
- Open Access
- 13 July 2026
- Published by Springer Nature in Beni-Suef University Journal of Basic and Applied Sciences
- Vol. 15 (1) , 75
Integrative strategies in herbal product-based Drug discovery: from computational models to molecular insights
Background: Conventional drug discovery process is associated with high costs, lengthy development timelines, and high failure rates mainly for complex multifactorial diseases. These challenges highlight the existing need for various innovative discovery strategies. Natural product continues to play an important role in discovery of drugs, with natural compounds and their derivatives accounting for approximately one-third of all small-molecule drugs that were approved from 1981 to 2019. Main Body: Currently, computational and systems-based approaches are being increasingly incorporated in various steps of herbal-drug discovery. These approaches include molecular docking, virtual screening, quantitative structure-activity relationship (QSAR) modelling, network pharmacology, and bioactivity prediction using machine learning. Other emerging technologies such as genome editing and synthetic biology also provide additional opportunities to access and optimize valuable natural-product metabolites. Together, these tools can aid in identifying candidate molecules, elucidate potential mechanisms, and formulation development, although all of it requires experimental validation. Herbal medicines can modulate multiple molecular targets, hence can be advantageous for complex diseases. Analytical techniques such as hyphenated spectroscopy and metabolomics can further contribute to standardization and quality control. Nanocarrier systems and pharmacogenomic approaches can increase bioavailability and support more personalized therapeutic strategies. This review highlights integrated approaches for improving discovery, validation, and herbal therapeutic development. Conclusion: The combination of traditional knowledge with computational and analytical approaches provides a practical framework for herbal product-based drug discovery. Continued progress will depend on standardization, reproducible methodologies, and robust clinical evidence.
- 13 July 2026
- Published by Springer Nature in Beni-Suef University Journal of Basic and Applied Sciences
- Vol. 15 (1) , 75
Open AccessIntegrative strategies in herbal product-based Drug discovery: from computational models to molecular insights
Background: Conventional drug discovery process is associated with high costs, lengthy development timelines, and high failure rates mainly for complex multifactorial diseases. These challenges highlight the existing need for various innovative discovery strategies. Natural product continues to play an important role in discovery of drugs, with natural compounds and their derivatives accounting for approximately one-third of all small-molecule drugs that were approved from 1981 to 2019. Main Body: Currently, computational and systems-based approaches are being increasingly incorporated in various steps of herbal-drug discovery. These approaches include molecular docking, virtual screening, quantitative structure-activity relationship (QSAR) modelling, network pharmacology, and bioactivity prediction using machine learning. Other emerging technologies such as genome editing and synthetic biology also provide additional opportunities to access and optimize valuable natural-product metabolites. Together, these tools can aid in identifying candidate molecules, elucidate potential mechanisms, and formulation development, although all of it requires experimental validation. Herbal medicines can modulate multiple molecular targets, hence can be advantageous for complex diseases. Analytical techniques such as hyphenated spectroscopy and metabolomics can further contribute to standardization and quality control. Nanocarrier systems and pharmacogenomic approaches can increase bioavailability and support more personalized therapeutic strategies. This review highlights integrated approaches for improving discovery, validation, and herbal therapeutic development. Conclusion: The combination of traditional knowledge with computational and analytical approaches provides a practical framework for herbal product-based drug discovery. Continued progress will depend on standardization, reproducible methodologies, and robust clinical evidence.
- Open Access
- 14 April 2026
- Published by Elsevier in SSRN Electronic Journal
Integrated HPTLC, HPLC, and LC–MS Approach for the Identification and UV-Based Antioxidant Evaluation of Gallic Acid
Gallic acid is a naturally occurring phenolic compound abundantly present in medicinal plants and herbal formulations, where it plays significantly role in contributing to a wide range of pharmacological activities. Therefore, the development of robust and reliable analytical techniques for its identification and quantification is essential. The objective of the present study was to develop and validate analytical methods for the identification and quantification of gallic acid using HPTLC, HPLC and LC–MS. For HPTLC analysis, gallic acid was separated on silica gel 60 F254 precoated plates using a mobile phase of toluene: ethyl acetate: formic acid (4.5:5:0.5, v/v/v), which produced well-defined and compact bands. The plates were visualized under ultraviolet light at 254 nm and 366 nm, followed by densitometric scanning. HPLC conditions were optimized to ensure accurate, precise, and reproducible quantification of gallic acid in the sample matrix. LC–MS analysis was employed to confirm the molecular identity of gallic acid based on its characteristic mass spectral profile. All analytical methods were validated as per standard guidelines, including parameters such as linearity, precision, accuracy, and specificity and demonstrated satisfactory reproducibility and consistency. The present study introduces a novel integrated analytical approach combining HPTLC, HPLC, and LC–MS for the precise identification and validation of gallic acid, coupled with UV-based antioxidant evaluation. Unlike existing methods that rely on single or dual techniques, this work establishes a unified, cross-validated platform that enhances analytical accuracy, structural confirmation, and bioactivity correlation, thereby addressing key limitations in current phytochemical analysis and advancing the field of analytical chemistry. In conclusion, the developed methods are reliable, validated, and suitable for the routine estimation of gallic acid in plant-based formulations, with potential applications in quality control and standardization of herbal products.
- 14 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessIntegrated HPTLC, HPLC, and LC–MS Approach for the Identification and UV-Based Antioxidant Evaluation of Gallic Acid
Gallic acid is a naturally occurring phenolic compound abundantly present in medicinal plants and herbal formulations, where it plays significantly role in contributing to a wide range of pharmacological activities. Therefore, the development of robust and reliable analytical techniques for its identification and quantification is essential. The objective of the present study was to develop and validate analytical methods for the identification and quantification of gallic acid using HPTLC, HPLC and LC–MS. For HPTLC analysis, gallic acid was separated on silica gel 60 F254 precoated plates using a mobile phase of toluene: ethyl acetate: formic acid (4.5:5:0.5, v/v/v), which produced well-defined and compact bands. The plates were visualized under ultraviolet light at 254 nm and 366 nm, followed by densitometric scanning. HPLC conditions were optimized to ensure accurate, precise, and reproducible quantification of gallic acid in the sample matrix. LC–MS analysis was employed to confirm the molecular identity of gallic acid based on its characteristic mass spectral profile. All analytical methods were validated as per standard guidelines, including parameters such as linearity, precision, accuracy, and specificity and demonstrated satisfactory reproducibility and consistency. The present study introduces a novel integrated analytical approach combining HPTLC, HPLC, and LC–MS for the precise identification and validation of gallic acid, coupled with UV-based antioxidant evaluation. Unlike existing methods that rely on single or dual techniques, this work establishes a unified, cross-validated platform that enhances analytical accuracy, structural confirmation, and bioactivity correlation, thereby addressing key limitations in current phytochemical analysis and advancing the field of analytical chemistry. In conclusion, the developed methods are reliable, validated, and suitable for the routine estimation of gallic acid in plant-based formulations, with potential applications in quality control and standardization of herbal products.
- 27 February 2026
- Published by Wiley in Biomedical Chromatography
- Vol. 40 (4) , e70393
Quality by Design–Based RP‐HPLC Method for Simultaneous Estimation of 4‐Hydroxytamoxifen and Thymoquinone in Liposomal Formulation
Developing a method for the simultaneous quantification of drugs in combination formulations is crucial for optimizing combination therapy. 4‐Hydroxytamoxifen (4‐OHT) and thymoquinone exhibit synergistic activity in breast cancer treatment, yet no robust analytical method exists for their simultaneous estimation in liposomal systems. This study aimed to design, optimize and validate an RP‐HPLC method for quantifying both drugs using an analytical quality by design (AQbD) approach. An analytical target profile (ATP) was defined, and risk assessment using an Ishikawa diagram identified mobile phase composition, flow rate and column temperature as critical parameters. Method optimization was performed using a Box–Behnken Design, evaluating effects on retention times, peak areas, tailing factors and resolution. Optimal conditions included a 90:10 methanol:aqueous mobile phase, 0.5 mL/min flow rate and 35°C column temperature. The method was validated per ICH Q2(R1) guidelines, demonstrating excellent sensitivity (LOD 0.69–0.29 μg/mL), accuracy (95%–105% recovery) and precision (RSD < 2%). The method was successfully applied for drug estimation in liposomal formulations, ex vivo permeation, cytotoxicity and cellular uptake studies. Liposomal gels showed high entrapment efficiency, enhanced drug release, permeation and cellular uptake. Analytical Eco‐Scale assessment confirmed excellent green performance.
- 27 February 2026
- Published by Wiley in Biomedical Chromatography
- Vol. 40 (4) , e70393
Quality by Design–Based RP‐HPLC Method for Simultaneous Estimation of 4‐Hydroxytamoxifen and Thymoquinone in Liposomal Formulation
Developing a method for the simultaneous quantification of drugs in combination formulations is crucial for optimizing combination therapy. 4‐Hydroxytamoxifen (4‐OHT) and thymoquinone exhibit synergistic activity in breast cancer treatment, yet no robust analytical method exists for their simultaneous estimation in liposomal systems. This study aimed to design, optimize and validate an RP‐HPLC method for quantifying both drugs using an analytical quality by design (AQbD) approach. An analytical target profile (ATP) was defined, and risk assessment using an Ishikawa diagram identified mobile phase composition, flow rate and column temperature as critical parameters. Method optimization was performed using a Box–Behnken Design, evaluating effects on retention times, peak areas, tailing factors and resolution. Optimal conditions included a 90:10 methanol:aqueous mobile phase, 0.5 mL/min flow rate and 35°C column temperature. The method was validated per ICH Q2(R1) guidelines, demonstrating excellent sensitivity (LOD 0.69–0.29 μg/mL), accuracy (95%–105% recovery) and precision (RSD < 2%). The method was successfully applied for drug estimation in liposomal formulations, ex vivo permeation, cytotoxicity and cellular uptake studies. Liposomal gels showed high entrapment efficiency, enhanced drug release, permeation and cellular uptake. Analytical Eco‐Scale assessment confirmed excellent green performance.
- Open Access
- 19 November 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (47) , 56932-56963
Harnessing Polymeric Dissolvable Microneedles: Precision Delivery of Therapeutics for Oral Ulcers
Oral ulcers are a prevalent and recurrent condition that significantly impacts the patient’s quality of life by causing pain, discomfort, and difficulty in eating, speaking, and brushing their teeth. These ulcers can be triggered by diverse etiologies, from trauma to autoimmune disorders, which complicate their management, and they often require targeted treatment to promote healing and alleviate pain. Conventional treatments, such as corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and topical analgesics, among others, rely on synthetic medications that provide temporary relief and require frequent reapplication, thereby limiting their effectiveness. Thus, the management of oral ulcers necessitates the need for innovative therapeutic approaches. Recent advancements in nanotechnology and transdermal drug delivery have led to the development of dissolving microneedles (MNs) loaded with nanotherapeutics for delivering active therapeutics directly to affected oral tissues as a novel strategy for treating oral ulcers. Dissolving MNs offer a minimally invasive, painless, and efficient method for delivering therapeutic agents directly to the ulcer site, enhancing drug bioavailability, and ensuring sustained release. These biodegradable MNs dissolve upon application, eliminating the need for repeated drug application and thereby improving patient compliance. The synergistic approach of nanotherapeutics encapsulated within dissolving MNs, including nanoparticles, exosomes, and liposomes, among others, effectively addresses the multifactorial nature of oral ulcers by ensuring localized treatment and mitigating the systemic side effects associated with conventional drug delivery methods. Taken together, this review aims to integrate the current knowledge of these innovative technologies while highlighting future directions for research and clinical applications in treating oral ulcers.
- 19 November 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (47) , 56932-56963
Open AccessHarnessing Polymeric Dissolvable Microneedles: Precision Delivery of Therapeutics for Oral Ulcers
Oral ulcers are a prevalent and recurrent condition that significantly impacts the patient’s quality of life by causing pain, discomfort, and difficulty in eating, speaking, and brushing their teeth. These ulcers can be triggered by diverse etiologies, from trauma to autoimmune disorders, which complicate their management, and they often require targeted treatment to promote healing and alleviate pain. Conventional treatments, such as corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and topical analgesics, among others, rely on synthetic medications that provide temporary relief and require frequent reapplication, thereby limiting their effectiveness. Thus, the management of oral ulcers necessitates the need for innovative therapeutic approaches. Recent advancements in nanotechnology and transdermal drug delivery have led to the development of dissolving microneedles (MNs) loaded with nanotherapeutics for delivering active therapeutics directly to affected oral tissues as a novel strategy for treating oral ulcers. Dissolving MNs offer a minimally invasive, painless, and efficient method for delivering therapeutic agents directly to the ulcer site, enhancing drug bioavailability, and ensuring sustained release. These biodegradable MNs dissolve upon application, eliminating the need for repeated drug application and thereby improving patient compliance. The synergistic approach of nanotherapeutics encapsulated within dissolving MNs, including nanoparticles, exosomes, and liposomes, among others, effectively addresses the multifactorial nature of oral ulcers by ensuring localized treatment and mitigating the systemic side effects associated with conventional drug delivery methods. Taken together, this review aims to integrate the current knowledge of these innovative technologies while highlighting future directions for research and clinical applications in treating oral ulcers.
- Open Access
- 7 January 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 161-173
NETWORK PHARMACOLOGY BASED COMPUTATIONAL STUDY TO INVESTIGATE THE POTENTIAL MECHANISM OF SYZYGIUM CARYOPHYLLATUM AGAINST COLON CANCER
Objective: Syzygium caryophyllatum, a traditional medicinal plant from the Myrtaceae family, is rich in potential phytoconstituents. Based on its ethnobotanical uses and documented pharmacological activities, present work was conducted to evaluate the probable mechanism of action of S. caryophyllatum to manage colon cancer by integrating network pharmacology and computational studies. Methods: The plant extract was prepared by Soxhlet extraction method and in vitro screening was performed using Sulforhodamine (SRB) Assay on HT 29 cancer cell lines. We have used super-PRED database, Cytoscape network analyser tool, string database and CytoHubba for performing network analysis for the extract compounds reported in GC-MS analysis. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and DAVID databases were used for gene set enrichment analysis. We have used Schrödinger suite Version 11.4's to perform computational studies. Results: The extract has demonstrated significant in vitro cytotoxic activity (IC50 value is 49.01 µg/ml) and the GC-MS analysis identified seventy-six distinct compounds. The Gene Ontology (GO) and KEGG demonstrated that the shared targets were strongly associated with key processes involved in colon cancer. The current study has identified Estrogen Receptor Alpha (ESR1), Heat Shock Protein 90 Alpha Family Class A Member 1 (HSP90AA1), Mitogen-activated protein kinase 3 (MAP3K), Epidermal Growth Factor Receptor (EGFR) and Signal transducer and activator of transcription 3 (STAT3) proteins as essential targets and 5,7-Dihydroxy-2-undecyl-4H-chromen-4-one, 7a,12-Dihydroindolo[2,3-a] quinolizine, 5-hydroxy-7-methoxy-2-methyl-8-(3-methylbutyl) chromen-4-one as key compounds. Docking studies of the compounds with core proteins completely supplemented their binding affinity and suggested strong interactions at the binding site. Conclusion: These outcomes highlight the multi-target, multi-compound, and multi-pathway approaches of S. caryophyllatum against colon cancer.
- 7 January 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 161-173
Open AccessNETWORK PHARMACOLOGY BASED COMPUTATIONAL STUDY TO INVESTIGATE THE POTENTIAL MECHANISM OF SYZYGIUM CARYOPHYLLATUM AGAINST COLON CANCER
Objective: Syzygium caryophyllatum, a traditional medicinal plant from the Myrtaceae family, is rich in potential phytoconstituents. Based on its ethnobotanical uses and documented pharmacological activities, present work was conducted to evaluate the probable mechanism of action of S. caryophyllatum to manage colon cancer by integrating network pharmacology and computational studies. Methods: The plant extract was prepared by Soxhlet extraction method and in vitro screening was performed using Sulforhodamine (SRB) Assay on HT 29 cancer cell lines. We have used super-PRED database, Cytoscape network analyser tool, string database and CytoHubba for performing network analysis for the extract compounds reported in GC-MS analysis. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and DAVID databases were used for gene set enrichment analysis. We have used Schrödinger suite Version 11.4's to perform computational studies. Results: The extract has demonstrated significant in vitro cytotoxic activity (IC50 value is 49.01 µg/ml) and the GC-MS analysis identified seventy-six distinct compounds. The Gene Ontology (GO) and KEGG demonstrated that the shared targets were strongly associated with key processes involved in colon cancer. The current study has identified Estrogen Receptor Alpha (ESR1), Heat Shock Protein 90 Alpha Family Class A Member 1 (HSP90AA1), Mitogen-activated protein kinase 3 (MAP3K), Epidermal Growth Factor Receptor (EGFR) and Signal transducer and activator of transcription 3 (STAT3) proteins as essential targets and 5,7-Dihydroxy-2-undecyl-4H-chromen-4-one, 7a,12-Dihydroindolo[2,3-a] quinolizine, 5-hydroxy-7-methoxy-2-methyl-8-(3-methylbutyl) chromen-4-one as key compounds. Docking studies of the compounds with core proteins completely supplemented their binding affinity and suggested strong interactions at the binding site. Conclusion: These outcomes highlight the multi-target, multi-compound, and multi-pathway approaches of S. caryophyllatum against colon cancer.